About AKAO

AKAO is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen's lead product candidate, for the treatment of serious lung, bloodstream, and urinary tract infections due to Enterobacteriaceae, including CRE. Achaogen's plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen's gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

AKAO is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
URTY ProShares UltraPro Russell2000 102.0 M 1.0199E+08 2,018 2018 0.0% 2.06984E-06 681 681
UWM ProShares Ultra Russell2000 179.7 M 1.79696E+08 2,017 2017 0.0% 3.07365E-06 1 K 1222
VHT Vanguard Health Care ETF 9.4 B 9.400001E+09 361 361 0.0% 1E-05 78 K 77996
VTWG Vanguard Russell 2000 Growth ETF 286.3 M 2.863E+08 1,245 1245 0.0% 2E-05 5 K 5337
VTWO Vanguard Russell 2000 ETF 1.6 B 1.6E+09 2,013 2013 0.0% 1E-05 17 K 17001
VTWV Vanguard Russell 2000 Value ETF 247.5 M 2.475E+08 1,376 1376 0.0% 1E-05 1 K 1250
ITOT iShares Core S&P Total U.S. Stock Market ETF 18.5 B 1.85179E+10 3,573 3573 0.0% 0 11 K 11478
IWC iShares Microcap ETF 909.3 M 9.09255E+08 1,452 1452 0.0% 0 39 K 39237
IWM iShares Russell 2000 ETF 43.0 B 4.30457E+10 2,006 2006 0.0% 0 316 K 316307
IWN iShares Russell 2000 Value ETF 9.1 B 9.14719E+09 1,371 1371 0.0% 0 19 K 18756
IWO iShares Russell 2000 Growth ETF 9.1 B 9.10544E+09 1,239 1239 0.0% 0 122 K 122377
IWV iShares Russell 3000 ETF 9.6 B 9.60936E+09 2,959 2959 0.0% 0 5 K 4940

Wait, Before You Leave...